Well-capitalized VaxInnate gets another $6M for its bacteria-based flu vaccines
New Jersey’s VaxInnate is developing inoculations to ward off seasonal and pandemic flu, dengue fever and Clostridium difficile. The well-capitalized company has raised a recent round of $6 million, according to a regulatory filing. The company genetically fuses vaccine antigens to flagellin, a protein that forms the flagella of a bacterium that’s known for being highly […]